Zydus Wellness (531335) Q4 97/98 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 97/98 earnings summary
3 Nov, 2026Executive summary
FY98 sales rose to Rs. 4,85,083 from Rs. 2,18,400; the year ended with a net loss of Rs. 78,83,943.
A Gujarat marketing channel was established, while a nationwide distribution network was being developed; working-capital facilities sanctioned late in the year eased liquidity pressure.
Financial highlights
Sales were Rs. 4,85,083 versus Rs. 2,18,400 in FY97; total income was Rs. 21,57,763, including Rs. 16,37,984 interest income.
Total expenditure was Rs. 1,00,41,706 and net loss was Rs. 78,83,943, versus prior-year profit after tax of Rs. 4,08,208.
Closing inventory increased to Rs. 22,71,562 from Rs. 40,000; cash and bank balances fell to Rs. 83,479 from Rs. 13,37,993.
Outlook and guidance
Nationwide distribution was targeted for establishment in the near term, building on the Gujarat marketing channel launched during FY98.
Latest events from Zydus Wellness
- Sales and EBITDA surged as gross margin expanded and brand growth continued.531335
Q2 26/27 - Revenue rose 42%, profit after tax doubled, and a Rs. 0.60/share dividend was proposed.531335
Q4 02/03 - Sales surged, but FY99 ended with a Rs 45,36,571 loss before tax.531335
Q4 98/99 - Higher sales and production accompanied a narrower loss, but operating cash flow remained negative.531335
Q4 99/00 - FY02 profit improved as new-product investment positioned the business for growth.531335
Q4 01/02 - Sales more than doubled as profits rose and product expansion broadened.531335
Q4 03/04 - Revenue rose 60.75% as capacity expansion and regional growth plans advanced.531335
Q4 04/05 - Revenue surged 49%, but profit eased amid advertising investment; Nutralite Premium launched.531335
Q4 06/07 - Sales grew 9.12%, profit held near flat, and Cadila Healthcare took a 61.56% stake.531335
Q4 05/06